BIIB vs ILMN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BIIB Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Growth & Margin, Options & Structure while ILMN counters with relative strength in Valuation, Momentum & Technical. Fundamentally, BIIB trades at 15.6x Forward P/E with 23.5% operating margin (+10.6% YoY revenue) versus ILMN at 33.5x Forward P/E and 19.1% operating margin (+4.2% YoY). In options structure, BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against ILMN sits in CONSOLIDATION (24th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BIIB Revenue | ILMN Revenue | BIIB Op. Margin | ILMN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $13.4B | $3.33B | 43.8% | 26.5% | BIIB |
| FY2019 | $14.4B | $3.54B | 49.0% | 27.8% | BIIB |
| FY2020 | $13.4B | N/A | 33.8% | N/A | BIIB |
| FY2021 | $11.0B | $3.24B | 25.9% | 17.9% | BIIB |
| FY2022 | $10.2B | $4.53B | 29.9% | -2.7% | BIIB |
| FY2023 | $9.84B | $4.50B | 11.8% | -23.7% | BIIB |
| FY2024 | $9.68B | $4.37B | 16.9% | -19.1% | BIIB |
| FY2025 | $9.89B | $4.34B | 13.1% | 18.6% | ILMN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BIIB | ILMN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $37.0B | $31.7B | Larger Scale | BIIB |
| Trailing P/E Ratio Valuation | 109.9x | 36.6x | Lower Multiple | ILMN |
| Forward P/E Ratio Valuation | 15.6x | 33.5x | Lower Multiple | BIIB |
| Revenue Growth (YoY) Growth | +10.6% | +4.2% | Higher Growth | BIIB |
| Operating Margin (TTM) Profitability | 23.5% | 19.1% | Higher Margin | BIIB |
| Net Profit Margin Profitability | 3.4% | 19.7% | Higher Margin | ILMN |
| Return on Equity (ROE) Capital Efficiency | 1.9% | 32.4% | Higher ROE | ILMN |
| 52-Week Range Position Momentum | 92% ($160โ$261) | 44% ($113โ$309) | Stronger Trend | BIIB |
| Beta / 30D Volatility Risk Regime | 0.27ฮฒ ยท 36% Vol | 1.34ฮฒ ยท 85% Vol | Lower Realized Risk | BIIB |
| Unified Institutional Score Composite Signal | 50.2 / 100 (HOLD) | 55.1 / 100 (HOLD) | Higher Composite | ILMN |